Increased Risk of Pulmonary Embolism, Death in RA Patients Reported in Tofacitinib Postmarketing Study - MPR - Monthly Prescribing Reference

Increased Risk of Pulmonary Embolism, Death in RA Patients Reported in Tofacitinib Postmarketing Study - MPR  Monthly Prescribing Reference

According to data from on an ongoing postmarketing safety trial conducted by Pfizer, tofacitinib dosed at 10mg twice daily was associated with an increased risk ...



Comments

Post a Comment

Popular posts from this blog

Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma - Global Banking And Finance Review

Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma    Global Banking And Finance Review Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
Read more